Evidence map›Paper›PMID 35061509›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.

Antonio Di Meglio, Julie Havas, Davide Soldato, Daniele Presti, Elise Martin, Barbara Pistilli, Gwenn Menvielle, Agnes Dumas, Cecile Charles, Sibille Everhard and 13 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01993498 (A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01993498 narecruitingnot on this map

A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer

TypeinterventionalSponsorUNICANCERRan2012 to 2034Enrolled14,750ConditionsBreast Cancer Nos Metastatic Recurrent, Early Lung CancerArmsblood sampling
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Diagnostic predictive models for cancer-related fatigue: current evidence and future directions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  3. Effects of Tai Chi Chuan on physical function and health in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Development and validation of a machine learning model to predict moderate-to-severe cancer-related fatigue in breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Development of a prediction model for clinically-relevant fatigue: a multi-cancer approach.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 3 countries.

Antonio Di MeglioINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0002-0233-3189
Julie HavasINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.
Davide SoldatoINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0002-2090-3245
Daniele PrestiINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0003-4442-6700
Elise MartinINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0001-9679-7226
Barbara PistilliINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0002-9184-7199
Gwenn MenvielleSorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.ORCID 0000-0002-3261-6366
Agnes DumasUniversite de Paris, ECEVE UMR 1123, INSERM, Paris, France.ORCID 0000-0001-7948-6952
Cecile CharlesINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0003-3126-1337
Sibille EverhardUNICANCER, Paris, France.ORCID 0000-0002-3151-5707
Anne-Laure MartinUNICANCER, Paris, France.ORCID 0000-0002-9302-8576
Charles CoutantCentre Georges-François Leclerc, Dijon, France.
Carole TarpinInstitut Paoli Calmettes, Marseille, France.
Laurence VanlemmensCentre Oscar Lambret, Lille, France.
Christelle LevyCentre François Baclesse, Caen, France.
Olivier RigalCentre Henri Becquerel, Rouen, France.
Suzette DelalogeINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0003-2106-9165
Nancy U LinDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2263-5413
Patricia A GanzUniversity of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-1841-4143
Ann H PartridgeDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4722-4824
Fabrice AndréINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0001-5795-8357
Stefan MichielsService de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.ORCID 0000-0002-6963-2968
Ines Vaz-LuisINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; University Paris-Saclay.ORCID 0000-0002-7194-2260
Inserm · FRDana-Farber Cancer Institute · USUniCancer Group · FRCentre François Baclesse · FRCentre Georges François Leclerc · FRCentre Henri BecquerelCentre Oscar Lambret · FRInstitut Pprime · FRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk. PATIENTS AND

methodsParticipants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score ≥ 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained associations with severe fatigue by bootstrapped Augmented Backward Elimination. Validation methods included 10-fold internal cross-validation, overoptimism-corrected area under the receiver operating characteristic curves, and external validation.

resultsAmong 5,640, 5,000, and 3,400 patients at T1, T2, and T3, respectively, the prevalence of post-treatment severe global fatigue was 35.6%, 34.0%, and 31.5% in the development cohort. Retained risk factors for severe global fatigue at T2 were severe pretreatment fatigue (adjusted odds ratio

conclusionWe propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue.

Indexed as

Breast NeoplasmsCancer SurvivorsFemaleHumansQuality of LifeSurvivorsSurvivorship

Identifiers

PMID35061509
PMCPMC8966972
OpenAlexW4207072189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.